Subscribe
Subscribe

Survivors’s plasma to treat ebola patients does not meet expectations

Ebola Tx is the largest clinical study ever performed with blood plasma of people that survived Ebola, to treat the disease. The study was performed in Guinea by the Institute of Tropical Medicine (ITM) in Antwerp. The results of the study, which took place in 2015 during the  Ebola epidemic, not only show that this treatment is feasible, but also that it presents no risk. The treatment causes very few side effects. However, the effectiveness needs to be further examined.

Ablynx initiates Phase IIb study of inhaled anti-RSV nanobody

ViroVet successfully raises €5 million in series A funding

ThromboGenics starts Diabetic Macular Edema trial phase II

Novosanis closes third round of seed funding

Promethera Biosciences and LifeLiver Sign Alliance

IP strategy for oligonucleotides

MDxHealth Announces Preliminary Update on 2016 Results and Appointment of CFO

Continued coverage of Celyad’s Patent assured

argenx launches Phase II study of ARGX-113 for the treatment of myasthenia gravis

$41 Million raised for a biotech start-up by founders without biotech background

CRISPR start-up Synthego raises $41 million

Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

Celyad Announces Registration of the first patient in the Belgian THINK trial

Celyad commences THINK trial with its cell-based CAR-T/NKR-2 immunotherapy 

Ablynx to present at the 35th annual J.P. Morgan Healthcare Conference

Ablynx will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday 12 January, at 1.30 am CET (Wednesday 11 January 2017 at 4:30 p.m. PST).

$12 million for Univercells’s vaccines